Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: A prognostic model

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 10, 2008, Pages 1143-1149

  Tibaldi, C ^a,d   Vasile, E ^a,d   Bernardini, I ^a,d   Orlandini, C ^b,d   Andreuccetti, M ^a,d   Falcone, A ^a,c,d  

^a Ospedale Civile   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d Istituto Toscano Tumori   (Italy)

Author keywords

Chemotherapy; Leukocyte count; Multivariate analysis; NSCLC; Prognostic factors; Prognostic model

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADRENAL GLAND; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; ELECTROCORTICOGRAPHY; FEMALE; HAZARD RATIO; HIGH RISK POPULATION; HISTOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SCORING SYSTEM; SEX; SKIN METASTASIS; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKOCYTE COUNT; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 50249146361     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0378-2     Document Type: Article

References (16)

1. V Alberola C Camps M Provencio D Isla R Rosell C Vadell I Bover A Ruiz-Casado P Azagra U Jimenez JL Gonzalez-Larriba P Diz F Cardenal A Artal A Carrato S Morales JJ Sanchez R de las Penas E Felip G Lopez-Vivanco Spanish Lung Cancer Group 2003 Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish lung cancer group phase III randomized trial J Clin Oncol 17 3207 3213
2. J Atzpodien P Royston T Wandert M Reitz 2003 Metastatic renal carcinoma comprehensive prognostic system Br J Cancer 88 348 353
3. Bunn PA Jr, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4:1087-1100
4. DR Cox 1972 Regression models and life tables J R Stat Soc 34 187 220
5. G Giaccone RS Herbst C Manegold G Scagliotti R Rosell V Miller RB Natale JH Schiller Von Pawel A Pluzanska U Gatzemeier J Grous JS Ochs SD Averbuch MK Wolf P Rennie A Fandi DH Johnson 2004 Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 777 784
6. RS Herbst G Giaccone JH Schiller RB Natale V Miller C Manegold G Scagliotti R Rosell I Oliff JA Reeves MK Wolf AD Krebs SD Averbuch JS Ochs J Grous A Fandi DH Johnson 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 785 794
7. A Jemal R Siegel E Ward 2006 Cancer statistics, 2006 CA Cancer J Clin 56 106 130
8. B Jeremic B Milicic A Dagovic J Aleksandrovic N Nikolic 2003 Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy J Cancer Clin Oncol 129 114 122
9. EL Kaplan P Meier 1958 Non parametric estimation from incomplete observations J Am Stat Assoc 53 457 481
10. I Kasuga S Makino H Kiyuokawa H Katoh Y Ebihara K Ohyashiki 2001 Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma Cancer 92 2399 2405
11. P Kosmidis N Mylonakis C Nicolaides C Kalophonos E Samantas J Boukovinas G Fountzilas D Skarlos T Economopoulos D Tsavdaridis P Papakostas C Bacoyiannis M Dimopoulos 2002 Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial J Clin Oncol 17 3578 3585
12. E Laack N Dickgreber T Muller A Knuth J Benk C Lorenz F Gieseler H Durk W Engel-Riedel K Dalhoff C Kortsik U Graeven M Burk T Dierlamm T Welte I Burkholder L Edler DK Hossfeld German and Swiss Lung Cancer Study Group 2004 Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine and cisplatin in the treatment of advanced non-small-cell lung cancer: from the german and swiss lung cancer study group J Clin Oncol 22 2348 2356
13. SJ Mandrecar SE Schild SL Hillman KL Allen RS Marks JA Mailliard JE Krook AW Maksymiuk K Chansky K Kelly AA Adjei JR Jett 2006 A prognostic model for advanced stage non-small cell lung cancer Cancer 107 781 792
14. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P, Klastersky J, for the European Lung Cancer Working Party (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 13:1221-1230
15. H Schmidt L Bastholt P Geertsen IJ Christensen S Larsen J Gehl H von der Maase 2005 Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model Br J Cancer 93 273 278
16. C Sederholm G Hillerdal K Lamberg K Kolbeck M Dufmats R Westberg SR Gawande 2005 Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish lung cancer study group J Clin Oncol 23 8380 8388